BioCentury | Apr 15, 2013
Clinical News

OncorMed, Cancer Research Campaign Technology, Duke University regulatory update

...products, and will share with Cancer Research and Duke any revenues generated from therapeutic licenses. Oncormed Inc....
BioCentury | Apr 15, 2013
Company News

Myriad Genetics, OncorMed diagnostics/imaging, cancer news

...District of Columbia (see BioCentury, Nov. 24). Myriad Genetics Inc. (MYGN), Salt Lake City, Utah OncorMed Inc....
BioCentury | Jun 1, 1999
Company News

Phytera management update

...Wetherbee as VP of business development, formerly VP of business development and strategic planning at Oncormed Inc. WIR...
BioCentury | Dec 7, 1998
Company News

Gene Logic, Rhone-Poulenc Rorer deal

...The companies expanded a 1997 agreement originally signed between RPR and Oncormed Inc., which GLGC acquired in...
BioCentury | Oct 5, 1998
Company News

Gene Logic, OncorMed deal

...will have 19.6 million shares outstanding after the acquisition. Gene Logic Inc. (GLGC), Gaithersburg, Md. Oncormed Inc....
BioCentury | Jul 13, 1998
Finance

Amylin's timing is tough

...transcription. OSIP closed Friday at $6.375, up 17 percent on the week . . . OncorMed...
BioCentury | Jul 13, 1998
Company News

Gene Logic, OncorMed deal

...relevance and profiles patients for pharmacogenomic or therapeutic purposes. Gene Logic Inc. (GLGC), Gaithersburg, Md. Oncormed Inc....
BioCentury | Jul 13, 1998
Company News

Gene Logic management update

...Inc. (GLGC), Gaithersburg, Md. Business: Drug discovery Transition: Douglas Dolginow, formerly president and CEO of Oncormed Inc....
BioCentury | Jun 15, 1998
Clinical News

OncorMed regulatory update

...relating to BRCA1 are exclusively licensed to Myriad Genetics Inc. (MYGN, Salt Lake City, Utah). Oncormed Inc....
BioCentury | Jun 1, 1998
Clinical News

OncorMed regulatory update

...the entire normal BRCA1 protein in humans. Mutations in BRCA1 are associated with breast cancer. Oncormed Inc....
Items per page:
1 - 10 of 53
BioCentury | Apr 15, 2013
Clinical News

OncorMed, Cancer Research Campaign Technology, Duke University regulatory update

...products, and will share with Cancer Research and Duke any revenues generated from therapeutic licenses. Oncormed Inc....
BioCentury | Apr 15, 2013
Company News

Myriad Genetics, OncorMed diagnostics/imaging, cancer news

...District of Columbia (see BioCentury, Nov. 24). Myriad Genetics Inc. (MYGN), Salt Lake City, Utah OncorMed Inc....
BioCentury | Jun 1, 1999
Company News

Phytera management update

...Wetherbee as VP of business development, formerly VP of business development and strategic planning at Oncormed Inc. WIR...
BioCentury | Dec 7, 1998
Company News

Gene Logic, Rhone-Poulenc Rorer deal

...The companies expanded a 1997 agreement originally signed between RPR and Oncormed Inc., which GLGC acquired in...
BioCentury | Oct 5, 1998
Company News

Gene Logic, OncorMed deal

...will have 19.6 million shares outstanding after the acquisition. Gene Logic Inc. (GLGC), Gaithersburg, Md. Oncormed Inc....
BioCentury | Jul 13, 1998
Finance

Amylin's timing is tough

...transcription. OSIP closed Friday at $6.375, up 17 percent on the week . . . OncorMed...
BioCentury | Jul 13, 1998
Company News

Gene Logic, OncorMed deal

...relevance and profiles patients for pharmacogenomic or therapeutic purposes. Gene Logic Inc. (GLGC), Gaithersburg, Md. Oncormed Inc....
BioCentury | Jul 13, 1998
Company News

Gene Logic management update

...Inc. (GLGC), Gaithersburg, Md. Business: Drug discovery Transition: Douglas Dolginow, formerly president and CEO of Oncormed Inc....
BioCentury | Jun 15, 1998
Clinical News

OncorMed regulatory update

...relating to BRCA1 are exclusively licensed to Myriad Genetics Inc. (MYGN, Salt Lake City, Utah). Oncormed Inc....
BioCentury | Jun 1, 1998
Clinical News

OncorMed regulatory update

...the entire normal BRCA1 protein in humans. Mutations in BRCA1 are associated with breast cancer. Oncormed Inc....
Items per page:
1 - 10 of 53